If so, we are looking for volunteers to take part in a research study for an investigational medication called ampreloxetine (also known as TD-9855) for people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF) who, upon standing experience dizziness, light-headedness, feeling faint, or feeling like you might black out due to low blood pressure.

In people with conditions such as PD, MSA and PAF the autonomic nervous system may not work as well at regulating your blood pressure. A result of this is that patients with conditions such as Parkinson’s disease, multiple system atrophy, and pure autonomic failure experience a sudden drop in blood pressure upon standing.

This can cause symptoms such as dizziness, light-headedness, feeling faint, or feeling like you might black out. This is called symptomatic neurogenic orthostatic hypotension (snOH).

GET STARTED-SEE IF YOU QUALIFY

No health insurance is required to participate. All study-related care will be provided by qualified medical professionals at no cost to you. You may be compensated for your time and travel.

Get started User

The SEQUOIA Study

The SEQUOIA Study will include patients with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF) who, upon standing experience dizziness, light-headeness, feeling faint, or feeling like they might black out due to low blood pressure. It will be conducted at study sites in multiple countries. All study-related care will be provided by specialty physicians and a dedicated study team.

If you live in Canada or the US and qualify for the study, you will be given information to allow you to visit a study clinic in your area to learn more about the study from a study doctor.
Who can take part in The SEQUOIA  Study? 

You may be eligible to take part in the SEQUOIA Study if you:

  • are at least 30 years of age
  • have been diagnosed with Parkinson’s disease, multiple system atrophy, or pure autonomic failure
  • upon standing, have symptoms such as dizziness, light-headedness, feeling faint, or feeling like you might black out.

Sign Up

This Screening tool is for Canada and US residents only. If you are not a Canada or US resident, please do not complete this form.

About The Study

The SEQUOIA Study is evaluating an investigational drug, taken by mouth, called ampreloxetine (also known as TD-9855), for people with PD, MSA, or PAF who, upon standing, have symptoms such as dizziness, light-headedness, feeling faint, or feeling like you might black out due to a drop in blood pressure. Patients who complete the SEQUOIA study may be eligible to enter into an additional ampreloxetine clinical trial.

  • 1
    You may be eligible if you are over the age of 30, have been diagnosed Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF), and upon standing, have symptoms such as dizziness, light-headedness, feeling faint, or feeling like you might black out.
  • 2
    All study-related care is provided at no cost. You do not need health insurance to participate.
  • 3
    Volunteers who take part in the study may be eligible to receive compensation for their time and travel.
  • 4
    Participants will receive all study-related care from a team of medical professionals at no cost. The study will require routine visits to a research center in your area.

Who can take part in
The SEQUOIA Study?

You have been diagnosed with Parkinson’s disease,multiple system atrophy,or pure autonomic failure

You are at least 30 years of age

Upon standing, have symptoms such as dizziness, light-headedness,feeling faint,or feeling like you might black out

 

Frequently Asked Questions

A Clinical research study (also called a clinical trial) is a medical study that helps to answer important questions about an investigational drug or device, such as: Does the treatment work or how effective is it compared to other drugs/devices?

What can you expect from the SEQUOIA Study?

If you choose to participate in the SEQUOIA Study, at visits, you will undergo general physical examination procedures to assess your wellbeing (e.g. height, weight, blood pressure).

All study-related care is provided at no cost to you. You do not need health insurance to participate.

Participation is entirely voluntary. Even if you decide to take part in this study, you can change your mind about participating at any time.

Patients who complete the SEQUOIA Study may be eligible to enter into an additional ampreloxetine clinical trial.

Volunteers who take part in the study may be compensated for travel costs and time in the study. Please discuss this with the study team when they contact you.

There is no cost to participate in the SEQUOIA Study. The study medication, study-related tests, assessments, and visits will be provided at no cost to you and your insurance company. If you decide to take part in the study, you will receive study-related care throughout the study from a team of experienced doctors and nurses.

The research team will be able to explain more about what the SEQUOIA Study will involve, and it is up to you to decide if whether or not you want to take part. Participation in this study is voluntary. Whether or not you decide to participate in this study will not affect your current or future relationships with your doctors. If you decide to participate, you are free to withdraw at any time without affecting those relationships.

There are risks and benefits of taking part in any clinical study. For example, your health may be more closely monitored than it would have been otherwise. You may also benefit from taking the investigational drug, though this is not guaranteed. The known risks and benefits of participation are outlined in the informed consent form (ICF) that you must read and sign before you can take part in this study.

We match you to a research center within a close travel distance from your home. If we are not currently running any trials in your area, we will keep you in our database and reach out to you if a TD-9855 study site in your area becomes available.

About PD, MSA, or PAF and Symptoms of dizziness, light-headedness, feeling faint, or feeling like you might black out, upon standing.

The nervous system is a complex and sophisticated system that is responsible for regulating and coordinating activities of the body. There are two major divisions of the nervous system, which consists of the central nervous system (the brain and spinal cord), and the peripheral nervous system (peripheral nerves and the autonomic nerves.)

Disorders of the nervous system not only affect the brain and spinal cord, but also may affect the eyes, ears and sensory receptors in the skin, joints and muscles.2 Your autonomic nervous system is also responsible for important body functions, such as controlling your heart rate and blood pressure.

In people with conditions such as Parkinson’s disease, multiple system atrophy, and pure autonomic failure the autonomic nervous system may not work as well at regulating their blood pressure. A result of this is that patients with conditions such as Parkinson’s disease, multiple system atrophy, and pure autonomic failure experience a sudden drop in blood pressure upon standing. This can cause symptoms such as dizziness, light-headedness, feeling faint, or feeling like they might black out. This is called symptomatic neurogenic orthostatic hypotension (snOH).

Other symptoms of snOH may include the following:
  • Problems with vision (blurring, seeing spots, tunnel vision, etc.)
  • Weakness
  • Fatigue
  • Trouble Concentrating
  • Head/neck discomfort
The SEQUOIA Study

is looking at an investigational drug called ampreloxetine (also known as TD-9855), for people with nervous system conditions who, upon standing, experience dizziness, light-headedness, feeling faint, feeling like you might black out or other symptoms due to a drop in blood pressure.